logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. A pharmacoepidemiologic study of trandolapril.

    Article - En anglais

    In this pharmacoepidemiologic, open-label cohort study, we monitored for at least 6 months 10,820 patients with hypertension who were prescribed trandolapril by their physician.

    The drug relationships of adverse events (AEs) were assessed by the physician and then by the Knoll-France Pharmacovigilance Department.

    All AEs, other than those rated as unlikely to be causally related, were coded by both the physician and Knoll as adverse drug reactions (ADRs).

    A total of 1217 (11.25%) patients reported 1349 AEs of which 1081 (79.10%) were classified as ADRs.

    ADRs were recorded for 954 (8.82%) patients.

    After the occurrence of AEs (in 60% of patients, cough was the reason), 529 (4.89%) patients discontinued treatment.

    Serious AEs were experienced by 59 (11.2%) patients, but only 5 (0.95%) patients experienced serious ADRs.

    The most frequently reported ADRs were cough (3.57%), asthenia (1.04%), dizziness (0.92%), headache (0.74%), and nausea (0.55%). Comparison of these results with those from a 1049-patient trandolapril long-term, open-label study that was performed for the drug licensing application revealed no differences in the overall nature and frequency of serious or nonserious AEs.

    Mots-clés Pascal : Trandolapril, Antihypertenseur, Chimiothérapie, Hypertension artérielle, Traitement, Toxicité, Homme, Inhibiteur angiotensin converting enzyme, Pharmacovigilance, Etude cohorte, Epidémiologie, France, Europe

    Mots-clés Pascal anglais : Trandolapril, Antihypertensive agent, Chemotherapy, Hypertension, Treatment, Toxicity, Human, ACE inhibitor, Pharmacovigilance, Cohort study, Epidemiology, France, Europe

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0520197

    Code Inist : 002B02F05. Création : 13/02/1998.